Company profile
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and
- CEO
- Mr. Michael Lau M.B.A., Ph.D.
- Headquarters
- Frankfurt am Main, Germany
- Employees
- 27
- IPO date
- Feb 19, 2025
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies